As of June 10, 2025, aTyr Pharma Inc (LIFE) reports a Net Margin of -14274.50%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of aTyr Pharma Inc's Net Margin
Over recent years, aTyr Pharma Inc's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2023-12-31 | -14274.50% |
| 2022-12-31 | -436.38% |
| 2021-12-31 | -155.07% |
| 2020-12-31 | -5619.05% |
This slight downward trend highlights how aTyr Pharma Inc manages its overall profitability and cost control over time.
Comparing aTyr Pharma Inc's Net Margin to Peers
To better understand aTyr Pharma Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| aTyr Pharma Inc (LIFE) | -14274.50% |
| Enzon Pharmaceuticals Inc (ENZN) | 2992.31% |
| Regeneron Pharmaceuticals Inc (REGN) | 31.07% |
| Amgen Inc (AMGN) | 12.24% |
| Abbvie Inc (ABBV) | 7.59% |
| Gilead Sciences Inc (GILD) | 1.67% |
Compared to its competitors, aTyr Pharma Inc's Net Margin is among the lowest compared to peers, which may indicate challenges in controlling expenses or competitive pricing pressures.